<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03558477</url>
  </required_header>
  <id_info>
    <org_study_id>YYPCT_YYD601_P1</org_study_id>
    <nct_id>NCT03558477</nct_id>
  </id_info>
  <brief_title>PK/PD Clinical Trial of YYD601 in Healthy Adult Male</brief_title>
  <official_title>A Dose Blocked-randomized, Open-label, Parallel Design Clinical Trial to Assess the Pharmacokinetic/Pharmacodynamic Properties and Safety of YYD601 After Oral Administration in Healthy Adult Male Volunteers(Phase 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yooyoung Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yooyoung Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dose block-randomized, open-label, parallel clinical trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study to evaluate comparatively a characteristics and safety of the PK/PD of
      single/repeated oral administration YYD601 and Nexium tab and the effects of food influence
      the PK/PD of YYD601 in healthy adult male.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2017</start_date>
  <completion_date type="Actual">February 7, 2018</completion_date>
  <primary_completion_date type="Actual">February 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each arm is assignted 10 persons[the percent of each arm is (treatmnet: comparator=4:1)]</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>half-life</measure>
    <time_frame>Evaluate the before/after treatment period(5 days per phase)</time_frame>
    <description>Blood sampling time: 1d, 5d, 12d, 16d(each 17 times) half-life(after single dose), (after repeated dose)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Evaluate the before/after treatment period(5 days per phase)</time_frame>
    <description>Blood sampling time: 1d, 5d, 12d, 16d(each 17 times) Tmax(after singlidose), Tmax.ss(after repeated dose)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration</measure>
    <time_frame>Evaluate the before/after treatment period(5 days per phase)</time_frame>
    <description>Blood sampling time: 1d, 5d, 12d, 16d(each 17 times) Cmax(after singlidose), Cmax.ss(after repeated dose) Cmin.ss(after single dose),Cmin.ss(after single dose)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Evaluate the before/after treatment period(5 days per phase)</time_frame>
    <description>Blood sampling time: 1d, 5d, 12d, 16d(each 17 times) AUClast(after singlidose), AUCt(after repeated dose) AUCinf(after single dose), AUCinf(after repeated dose)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of pH&gt;4 duration time</measure>
    <time_frame>Evaluate the before/after treatment period(5 days per phase)</time_frame>
    <description>pH&gt;4 duration time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change in serum gastrin level</measure>
    <time_frame>Evaluate the before/after treatment period(5 days per phase)</time_frame>
    <description>serum gastrin level</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse event monitoring check up the adverse events</measure>
    <time_frame>Evaluate the before/after treatment period(5 days per phase)</time_frame>
    <description>Adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse event monitoring check up the vital sign(blood-pressure, pulse rate, temparature)</measure>
    <time_frame>Evaluate the before/after treatment period(5 days per phase)</time_frame>
    <description>vital sign(blood-pressure, pulse rate, temparature)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse event monitoring check up the 12-lead EKG</measure>
    <time_frame>Evaluate the before/after treatment period(5 days per phase)</time_frame>
    <description>12-lead EKG</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse event monitoring check up the clinical laboratory test</measure>
    <time_frame>Evaluate the before/after treatment period(5 days per phase)</time_frame>
    <description>clinical laboratory test</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse event monitoring check up the physical</measure>
    <time_frame>Evaluate the before/after treatment period(5 days per phase)</time_frame>
    <description>physical</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse event monitoring check up the administraton about the combined drugs</measure>
    <time_frame>Evaluate the before/after treatment period(5 days per phase)</time_frame>
    <description>administraton about the combined drugs</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>Set 1(YYD601 1 &amp; Nexium)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Set 1: YYD601 1 &amp; Nexium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Set 2(YYD601 2 &amp; Nexium)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Set 2: YYD601 2 &amp; Nexium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Set 3(YYD601 3 &amp; Nexium)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Set 3:YYD601 3 &amp; Nexium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYD601 1</intervention_name>
    <description>YYD601 1</description>
    <arm_group_label>Set 1(YYD601 1 &amp; Nexium)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYD601 2</intervention_name>
    <description>YYD601 2</description>
    <arm_group_label>Set 2(YYD601 2 &amp; Nexium)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYD601 3</intervention_name>
    <description>YYD601 3</description>
    <arm_group_label>Set 3(YYD601 3 &amp; Nexium)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexium</intervention_name>
    <description>Nexium</description>
    <arm_group_label>Set 1(YYD601 1 &amp; Nexium)</arm_group_label>
    <arm_group_label>Set 2(YYD601 2 &amp; Nexium)</arm_group_label>
    <arm_group_label>Set 3(YYD601 3 &amp; Nexium)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy adult male above 19 years old when getting a screening test.

          -  Subjects who have over 50kg weight, included in the IBWÂ± 20% range.
             [IBW(kg)={height(cm)-100}x0.9

          -  Subjects who haven't any congenital or chronic disease, and any other disease
             following the medical examination.

          -  Subjects who are confirmed as a participant by the serum test, hematologital test,
             blood chemistry tests, urine tests, and clinical laboratory test, 12-lead EKG etc
             following the characteristics aboht the IP within the 3 weeks before investogator
             products are administrated.

          -  Subjects who voluntarily decide to participated in this trial after comletely
             understand about this clinical trial.

        Exclusion criteria

          -  Subjects who are judged not suitable to participated in this trial.

          -  Other specific exlusion criteria is identified in the protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>healthy adult male</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyungpook national university hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>June 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>June 4, 2018</last_update_submitted>
  <last_update_submitted_qc>June 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

